SCHEMBL2121124

SCHEMBL2121124

CCc1ccc(-c2ccc(C=O)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.61
LMNA P02545 1/20 0.61
MAPT P10636 1/20 0.61
HPGD P15428 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
ALDH3A1 P30838 1/20 0.48
ALDH1A3 P47895 1/20 0.48
CYP2A6 P11509 3/20 0.46
EGFR P00533 1/20 0.44
GRIA4 P48058 1/20 0.44
UCHL1 P09936 1/20 0.43
DRD1 P21728 1/20 0.42
IGF1R P08069 1/20 0.42
PIM1 P11309 1/20 0.42
PIM2 Q9P1W9 1/20 0.42
TYR P14679 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
CYP2A13 Q16696 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ALDH5A1 P51649 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL154747 0.93 ALDH1A1 (0.68) ALDH1A1LMNAMAPTHPGDSMN1; SMN2
Ammonia Solution, Strong SCHEMBL29186824 0.91 ALDH1A1 (0.66) ALDH1A1LMNAMAPTHPGDSMN1; SMN2
SCHEMBL8361863 0.90 ALDH1A1 (0.55) ALDH1A1LMNAMAPTHPGDSMN1; SMN2
SCHEMBL13805753 0.90 ALDH1A1 (0.55) ALDH1A1LMNAMAPTHPGDSMN1; SMN2
SCHEMBL29174340 0.86 ALDH1A1 (0.61) ALDH1A1LMNAMAPTHPGDSMN1; SMN2
P-Xylene SCHEMBL7180224 0.84 CYP2A6 (0.70) ALDH1A1LMNAMAPTHPGDSMN1; SMN2
SCHEMBL7750869 0.83 ALDH1A1 (0.61) ALDH1A1LMNAMAPTHPGDSMN1; SMN2
SCHEMBL5604295 0.83 ALDH1A1 (0.45) ALDH1A1LMNAMAPTHPGDSMN1; SMN2
SCHEMBL1813830 0.81 ALDH1A1 (0.61) ALDH1A1LMNAMAPTHPGDSMN1; SMN2
SCHEMBL833678 0.81 ALDH1A1 (0.71) ALDH1A1LMNAMAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234396-A1 Tetrhydropyridoindole Derivatives ACTELION PHARMACEUTICALS LTD (CH) 2010-09-16 US claimed
EP-1725553-B1 TETRAHYDROPYRIDOINDOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-05-07 EP claimed
US-20070191416-A1 Tetrahydropyridoindole derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2007-08-16 US claimed
EP-1725553-A1 TETRAHYDROPYRIDOINDOLE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2006-11-29 EP claimed
WO-2005095397-A1 TETRAHYDROPYRIDOINDOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2005-10-13 WO claimed
EP-0983507-A1 TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES Trega Biosciences, Inc. (US) 2000-03-08 EP claimed
WO-1998034111-A1 TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-08-06 WO claimed
CN-118666841-A Indole-tetramic acid compound, preparation and medical application thereof 中国医学科学院药物研究所 2024-09-20 CN disclosed
WO-2017025167-A1 MATERIAL COMBINATION MERCK PATENT GMBH (DE) 2017-02-16 WO disclosed
US-20140178606-A1 CELLULOSE ACYLATE FILM, POLARIZER, AND LIQUID CRYSTAL DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2014-06-26 US disclosed
US-8477275-B2 Optical film and liquid crystal display device FUJIFILM CORPORATION (JP) 2013-07-02 US disclosed
US-20130128359-A1 OPTICAL FILM, POLARIZING PLATE, AND LIQUID CRYSTAL DISPLAY APPARATUS FUJIFILM CORPORATION (JP) 2013-05-23 US disclosed
US-8420187-B2 Cellulose acylate composition, cellulose acylate film, and its applications FUJIFILM CORPORATION (JP) 2013-04-16 US disclosed
EP-1055660-A1 Process for producing highly pure aromatic polycarboxylic acid MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2000-11-29 EP disclosed
EP-0983507-A1 TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES Trega Biosciences, Inc. (US) 2000-03-08 EP disclosed
EP-0942924-A2 METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS Elan Pharmaceuticals, Inc. (US) 1999-09-22 EP disclosed
US-5925527-A SCREENING NEW PHARMACEUTICALS TREGA BIOSCIENCES, INC. (US) 1999-07-20 US disclosed
WO-1998022494-A9 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS 1998-08-20 WO disclosed
WO-1998034111-A1 TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-08-06 WO disclosed
WO-1998022494-A2 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS ELAN PHARMACEUTICALS, INC. (US) 1998-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234396-A1 Tetrhydropyridoindole Derivatives TPH2, TPH1, HTR5A ALDH1A1 987/4885LMNA 3190/4885MAPT 375/4885
US-20070191416-A1 Tetrahydropyridoindole derivatives TPH2, TPH1, HTR2C ALDH1A1 927/4885LMNA 3204/4885MAPT 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.